

# Sharon X Xie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12008725/publications.pdf>

Version: 2024-02-01

52  
papers

6,979  
citations

101543  
36  
h-index

175258  
52  
g-index

53  
all docs

53  
docs citations

53  
times ranked

8861  
citing authors

#	ARTICLE	IF	CITATIONS
1	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	7.7	12
2	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
3	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathologica, 2022, 143, 15-31.	7.7	29
4	The development and convergence of co-pathologies in Alzheimer's disease. Brain, 2021, 144, 953-962.	7.6	76
5	Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018. Epilepsy and Behavior, 2020, 113, 107550.	1.7	4
6	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain, 2020, 143, 2844-2857.	7.6	44
7	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
8	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. Movement Disorders, 2020, 35, 1618-1625.	3.9	31
9	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. Journal of Neuropathology and Experimental Neurology, 2020, 79, 296-304.	1.7	35
10	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	5.3	88
11	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Annals of Neurology, 2019, 85, 801-811.	5.3	52
12	CSF tau and $\beta$ -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology, 2018, 90, e1038-e1046.	1.1	68
13	APOE $\epsilon$ 4, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	3.9	35
14	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	7.6	448
15	Evaluating the Patterns of Aging-Related Tau Astroglial Pathology Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	1.7	98
16	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. Journal of Parkinson's Disease, 2017, 7, 385-395.	2.8	21
17	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
18	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	5.3	51

#	ARTICLE	IF	CITATIONS
19	Regional brain amyloid- $\beta$ accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE, 2017, 12, e0177924.	2.5	33
20	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 21-26.	2.2	42
21	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. Movement Disorders, 2016, 31, 126-134.	3.9	20
22	Research consent capacity varies with executive function and memory in Parkinson's disease. Movement Disorders, 2016, 31, 414-417.	3.9	12
23	Amyloid- $\beta$ Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2016, 3, 367-375.	1.5	28
24	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	2.5	25
25	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	2.6	67
26	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	7.7	65
27	Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015, 85, 1276-1282.	1.1	197
28	Naltrexone for impulse control disorders in Parkinson disease. Neurology, 2014, 83, 826-833.	1.1	74
29	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	7.7	60
30	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.8	167
31	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	1.6	47
32	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain, 2013, 136, 2697-2706.	7.6	609
33	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain, 2012, 135, 3749-3756.	7.6	228
34	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	5.3	401
35	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain, 2012, 135, 807-818.	7.6	226
36	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	3.6	325

#	ARTICLE	IF	CITATIONS
37	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. <i>Brain</i> , 2012, 135, 170-180.	7.6	149
38	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. <i>Acta Neuropathologica</i> , 2012, 124, 23-35.	7.7	161
39	Questionnaire for impulsive-compulsive disorders in Parkinson's Disease "Rating Scale. <i>Movement Disorders</i> , 2012, 27, 242-247.	3.9	263
40	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2012, 123, 395-407.	7.7	104
41	Building an integrated neurodegenerative disease database at an academic health center. <i>Alzheimer's and Dementia</i> , 2011, 7, e84-93.	0.8	63
42	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. <i>Acta Neuropathologica</i> , 2011, 121, 509-517.	7.7	52
43	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. <i>Acta Neuropathologica</i> , 2011, 122, 737-745.	7.7	15
44	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1562.	4.5	180
45	Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental Illness. <i>Archives of Neurology</i> , 2010, 67, 1238-50.	4.5	90
46	Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 278-286.	1.8	21
47	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. <i>Journal of Neuroscience</i> , 2010, 30, 13861-13866.	3.6	256
48	Rate of Decline in Alzheimer Disease Measured by a Dementia Severity Rating Scale. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 268-274.	1.3	32
49	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. <i>Archives of Neurology</i> , 2009, 66, 180-9.	4.5	232
50	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 636-41.	4.5	251
51	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. <i>Acta Neuropathologica</i> , 2007, 114, 221-229.	7.7	378
52	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 227-231.	7.1	374